$SIOX News
Last published 2y ago
- 2y agoSIOXSio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per ShareGlobeNewswirePARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the
- 3y agoSIOXSio Gene Therapies Announces Fiscal Third Quarter 2022 Financial ResultsGlobeNewswire– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period
- 3y agoSIOXSio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and DissolutionGlobeNewswireNEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic
- 4y agoSIOXSio Gene Therapies Announces Fiscal Second Quarter 2022 Financial ResultsGlobeNewswire- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior year period - Strong
- 4y agoSIOXSio Gene Therapies Announces Fiscal First Quarter 2022 Financial ResultsGlobeNewswire— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:
- 4y agoSIOXSio Gene Therapies Announces Fiscal Year 2021 Year-End Financial ResultsGlobeNewswireNEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth Quarter Financial Summary For the fourth fisca
- 4y agoSIOXSio Gene Therapies Provides Corporate UpdateGlobeNewswire-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB Securities to advise it on a range of strategic alternatives to maximize stockholder value-Company had cash
- 4y agoSIOXSio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial ResultsGlobeNewswireCompany prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease $81.9 million of cash and cash equivalents as of December
- 4y agoSIOXSio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022GlobeNewswireNEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today anno
- 4y agoSIOXSio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO TransitionGlobeNewswire– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease, respectively; and to terminate AXO-Lenti-PD license ag
- 4y agoFLGCNRBOPAYSPSTV+1Thinking about buying stock in Plus Therapeutics, Neurobo Pharmaceuticals, Flora Growth, Paysign, or Sio Gene Therapies?PR NewswireNEW YORK, Jan. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTV, NRBO, FLGC, PAYS, and SIOX.
- 5y agoSIOXSio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial ResultsGlobeNewswire– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF – Granted Fast Track Designation for both AXO-AAV
- 5y agoSIOXSio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson's DiseaseGlobeNewswire- Completed three successful GMP campaigns using suspension-based manufacturing process- All batches achieved target titers and have successfully completed fill and finish- Qualified Person (QP) certification of at least one batch of clinical trial mater
- 5y agoSIOXSio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 GangliosidosisGlobeNewswire- Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations- Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases NEW YORK and DURHAM, N.C., Nov. 01, 2021
- 5y agoSIOXSio Gene Therapies Announces Reorganization of R&D GroupGlobeNewswireNEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, announced to
- 5y agoINMKDMNNXTPSENS+1Thinking about buying stock in Nextplay Technologies, Sio Gene Therapies, Kadmon, Senseonics, or InMed Pharmaceuticals?PR NewswireNEW YORK, Oct. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NXTP, SIOX, KDMN, SENS, and INM. T
- 5y agoSIOXSio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 GangliosidosisGlobeNewswireNEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announ
- 5y agoSIOXSio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 GangliosidosisGlobeNewswireConsistent dose-dependent improvements across biomarker measures Normalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and h
- 5y agoSIOXUPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021GlobeNewswireNEW YORK, and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today annou
- 5y agoSIOXSio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021GlobeNewswireNEW YORK and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announ
- 5y agoSIOXSio Gene Therapies to Participate in Upcoming ConferencesGlobeNewswireNEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative disease
- 5y agoSIOXSio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene TherapyGlobeNewswire- Study has now enrolled a total of nine patients across low-dose and high-dose cohorts- On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1 cohort in October 2021 NEW YORK, and DURHAM, N.C.
- 5y agoSIOXSio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial ResultsGlobeNewswire– Completed targeted enrollment of Type II patients in ongoing dose-escalation study of AXO-AAV-GM1 in GM1 gangliosidosis – On track to report 12-month topline safety, biomarker, and clinical outcomes data from low-dose cohort of AXO-AAV-GM1 i
- 5y agoCLSDOSMTPSACSIOX+1Thinking about buying stock in Osmotica Pharmaceuticals, Property Solutions Acquisition, Sio Gene Therapies, Clearside Biomedical, or Sorrento Therapeutics?PR NewswireNEW YORK, June 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSMT, PSAC, SIOX, CLSD, and SRNE.
- 5y agoAGTCAMPECYTHELOX+1Thinking about buying stock in Eloxx Pharmaceuticals, Sio Gene Therapies, Ampio Pharmaceuticals, Applied Genetic Technologies, or Cyclo Therapeutics?PR NewswireNEW YORK, June 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ELOX, SIOX, AMPE, AGTC, and CYTH.
- 5y agoSIOXSio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key MilestonesGlobeNewswire– Multiple GM1 gangliosidosis program milestones expected in FY2021, including 12-month data updates from the ongoing dose-escalation study and meeting with FDA to align on registrational pathway – Strong cash position with $119 million of cash an
- 5y agoSIOXSio Gene Therapies to Present at the UBS Global Healthcare Virtual ConferenceGlobeNewswireNEW YORK and RESEARCH TRIANGLE PARK, N.C, May 19, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases,
- 5y agoSIOXSio Gene Therapies Announces CSF Reductions in GM1 Ganglioside from Clinical Trial of AXO-AAV-GM1 Gene TherapyGlobeNewswire- GM1 ganglioside in CSF reduced in 4 out of 5 children treated with the lowest dose at 6 months follow-up- Direct evidence of biochemical effect in the CNS suggests intravenous gene therapy may address both the systemic and neurological manifestations o
- 5y agoSIOXSio Gene Therapies Announces Four Upcoming Oral Presentations at the 24th Annual Meeting of the American Society of Gene and Cell TherapyGlobeNewswireNEW YORK, and RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative dise
- 5y agoSIOXSio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program MilestonesGlobeNewswireCompany had $120.9 million of cash and cash equivalents as of March 12, 2021Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company...
- 5y agoSIOXSio Gene Therapies to Participate in Upcoming Investor & Scientific ConferencesGlobeNewswireNEW YORK and RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...
- 5y agoSIOXSio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireNEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...
- 5y agoSIOXSio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020GlobeNewswire- Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway...
- 5y agoSIOXSio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle TherapeuticsGlobeNewswireNEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...
- 5y agoSIOXSio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)GlobeNewswire- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies- Expect to continue patient identification, screening, and enrollment in Stage 1 of the study...
- 5y agoSIOXSio Gene Therapies to Sell Arvelle Stake as Part of Angelini Pharma’s Acquisition of Arvelle TherapeuticsGlobeNewswireCompany to receive up to $20 million in upfront and milestone payments from non-dilutive transactionTransaction extends cash runway into 2022 NEW YORK, N.Y. and RESEARCH TRIANGLE PARK, N.C., Jan. ...
- 5y agoCNSPSIOXHTBXBMY+1Glioblastoma Multiforme (GBM) Treatments Advancing as FDA Steps Up Measures Due to Rising IncidencesPR NewswireGlioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two...
- 5y agoSIOXSio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 GangliosidosisGlobeNewswire- Generally well-tolerated with a favorable safety profile in five patients- Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6,...
- 5y agoSIOXSio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 GangliosidosisGlobeNewswireOn-track to report topline results from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a...
- 5y agoAXGTSIOXSio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific AdvisorGlobeNewswireA pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapyDr. Gao recently served as President of the American Society for Gene and...
- 5y agoAXGTSIOXSio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020GlobeNewswireContinued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseasesCompleted rebranding to Sio Gene Therapies as part of...